Cost-effectiveness analysis of COVID-19 booster doses and oral antivirals: Case studies in the Indo-Pacific
Our results support that COVID-19 booster programs are cost-effective in middle-income settings. Oral antivirals demonstrate the potential to be cost-effective if procured at or below a middle-income reference price of US$250 per schedule. Further research should quantify the rates of wastage or misuse of oral COVID-19 antivirals in middle-income settings.
Authors
- Kamalini Lokuge (ORCID: https://orcid.org/0000-0002-6287-1296)
- Gizem Mayis Bilgin (ORCID: https://orcid.org/0000-0001-6824-4376)
- Syarifah Liza Munira (ORCID: https://orcid.org/0000-0003-3359-4290)
- Kathryn Glass (ORCID: https://orcid.org/0000-0001-5905-1310)
Institutions
- Australian National University (AU)
- University of Indonesia (ID)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1371/journal.pone.0294091
- Primary Topic
- COVID-19 epidemiological studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00